Earnings ·
iBio, Inc. reported financial results for the fiscal year ended June 30, 2026, revealing a net loss of $33.0 million…
IBIOiBio, Inc.
iBio, Inc. reported financial results for the fiscal year ended June 30, 2026, revealing a net loss of $33.0 million compared to $18.4 million in the prior year. Revenue declined to approximately $0.1 million from $0.4 million, while R&D expenses surged to $19.6 million due to increased consulting costs and development milestones for programs IBIO-610 and IBIO-600. The company recorded a $5.0 million impairment on the IBIO-101 intangible asset but held approximately $88.0 million in cash and investments as of June 30, 2026. Corporate updates included the appointment of Molly Carr, M.D., as Chief Medical Officer and Elizabeth Stoner, M.D., to the Board, alongside progress on clinical trials for its obesity and cardiometabolic pipeline. iBio is a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic, and cardiopulmonary diseases.